---
document_datetime: 2025-12-02 04:53:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel.html
document_name: vyndaqel.html
version: success
processing_time: 0.1643512
conversion_datetime: 2025-12-27 17:05:08.342661
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vyndaqel

[RSS](/en/individual-human-medicine.xml/66830)

##### Authorised

This medicine is authorised for use in the European Union

tafamidis Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vyndaqel](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-79310)
- [More information on Vyndaqel](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Vyndaqel. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vyndaqel.

This product originally had an [orphan designation for familial amyloid polyneuropathy](/en/medicines/human/orphan-designations/eu-3-06-401) , granted on 28 August 2006. This designation was withdrawn from the Community register of orphan medicinal products in November 2021 at the end of the 10-year period of market exclusivity.

Expand section

Collapse section

## What is Vyndaqel?

Vyndaqel is a medicine that contains the active substance tafamidis. It is available as capsules (20 mg).

## What is Vyndaqel used for?

Vyndaqel is used to delay nerve damage caused by transthyretin amyloidosis, a hereditary disease in which fibres called amyloid build up in tissues around the body including around the nerves. Vyndaqel is used in adult patients with the early stage of nerve disease (stage 1).

Because the number of patients with transthyretin amyloidosis is low, the disease is considered 'rare', and Vyndaqel was designated an 'orphan medicine' (a medicine used in rare diseases) on 28 August 2006.

The medicine can only be obtained with a prescription.

## How is Vyndaqel used?

Treatment should be started and supervised by a doctor knowledgeable in the management of patients with this disease. The recommended dose is one capsule once a day.

## How does Vyndaqel work?

In patients with transthyretin amyloidosis, a blood protein called transthyretin is defective and breaks easily. The broken protein forms a fibrous substance called amyloid that is deposited in tissues and organs around the body, including around nerves, where it interferes with their normal functions.

The active substance in Vyndaqel, tafamidis, is a transthyretin stabilizer. It attaches to transthyretin, which prevents the protein from breaking up, thereby stopping the formation of amyloid and slowing down the progression of the nerve disease.

## How has Vyndaqel been studied?

Vyndaqel was compared with placebo (a dummy treatment) in 128 patients with transthyretin amyloidosis. The main measure of effectiveness was based on an assessment of the patients' nerve damage and quality of life after 18 months of treatment.

## What benefit has Vyndaqel shown during the studies?

Vyndaqel was more effective than placebo at treating patients with transthyretin amyloidosis. In 45% of patients taking Vyndaqel, nerve function either improved or stabilised, compared with 30% of patients taking placebo. The results did not include patients with more severe disease who left the study early because they needed to undergo a liver transplant.

## What is the risk associated with Vyndaqel?

The most common side effects with Vyndaqel (seen in more than 1 patient in 10) are urinary tract infection (infection of the structures that carry urine), vaginal infection, upper abdominal pain (stomach ache) and diarrhoea. For the full list of all side effects and restrictions with Vyndaqel, see the package leaflet.

## Why has Vyndaqel been approved?

The CHMP noted that, apart from in patients who left the study because they needed a liver transplant, Vyndaqel was more effective than placebo in delaying nerve damage in patients with transthyretin amyloidosis. The medicine presented no major safety concerns and the risks were considered to be manageable. The CHMP therefore concluded that the benefits of Vyndaqel are greater than its risks and recommended that it be granted marketing authorisation.

Vyndaqel has been authorised under 'exceptional circumstances'. This means that because transthyretin amyloidosis is rare, for scientific reasons, it has not been possible to obtain complete information about Vyndaqel. Every year, the European Medicines Agency will review any new information that may become available and this summary will be updated as necessary.

## What information is still awaited for Vyndaqel?

The company that makes Vyndaqel will carry out a study on the effects of the medicine in a subgroup of patients with certain genetic mutations. The company will also provide long-term post-marketing safety data.

## What measures are being taken to ensure the safe and effective use of Vyndaqel?

The company that markets Vyndaqel will provide educational material to all doctors expected to prescribe Vyndaqel. The material will include a leaflet containing information on the risks of the medicine including the risks to the unborn baby and on how to contribute to a post-marketing study and a surveillance programme for pregnant women.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vyndaqel have also been included in the summary of product characteristics and the package leaflet.

## Other information about Vyndaqel

The European Commission granted a marketing authorisation valid throughout the European Union for Vyndaqel on 16 November 2011.

For more information about treatment with Vyndaqel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Vyndaqel : EPAR - Summary for the public

English (EN) (78.69 KB - PDF)

**First published:** 18/11/2011

**Last updated:** 02/08/2016

[View](/en/documents/overview/vyndaqel-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-489)

български (BG) (103.94 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/bg/documents/overview/vyndaqel-epar-summary-public_bg.pdf)

español (ES) (77.87 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/es/documents/overview/vyndaqel-epar-summary-public_es.pdf)

čeština (CS) (103.44 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/cs/documents/overview/vyndaqel-epar-summary-public_cs.pdf)

dansk (DA) (77.01 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/da/documents/overview/vyndaqel-epar-summary-public_da.pdf)

Deutsch (DE) (78.75 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/de/documents/overview/vyndaqel-epar-summary-public_de.pdf)

eesti keel (ET) (76.01 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/et/documents/overview/vyndaqel-epar-summary-public_et.pdf)

ελληνικά (EL) (107.66 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/el/documents/overview/vyndaqel-epar-summary-public_el.pdf)

français (FR) (78.29 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/fr/documents/overview/vyndaqel-epar-summary-public_fr.pdf)

hrvatski (HR) (105.84 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/hr/documents/overview/vyndaqel-epar-summary-public_hr.pdf)

italiano (IT) (77.32 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/it/documents/overview/vyndaqel-epar-summary-public_it.pdf)

latviešu valoda (LV) (99.69 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/lv/documents/overview/vyndaqel-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (101.58 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/lt/documents/overview/vyndaqel-epar-summary-public_lt.pdf)

magyar (HU) (98.95 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/hu/documents/overview/vyndaqel-epar-summary-public_hu.pdf)

Malti (MT) (104.08 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/mt/documents/overview/vyndaqel-epar-summary-public_mt.pdf)

Nederlands (NL) (77.5 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/nl/documents/overview/vyndaqel-epar-summary-public_nl.pdf)

polski (PL) (103.93 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/pl/documents/overview/vyndaqel-epar-summary-public_pl.pdf)

português (PT) (77.98 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/pt/documents/overview/vyndaqel-epar-summary-public_pt.pdf)

română (RO) (100.28 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/ro/documents/overview/vyndaqel-epar-summary-public_ro.pdf)

slovenčina (SK) (102.79 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/sk/documents/overview/vyndaqel-epar-summary-public_sk.pdf)

slovenščina (SL) (98.36 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/sl/documents/overview/vyndaqel-epar-summary-public_sl.pdf)

Suomi (FI) (76.62 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/fi/documents/overview/vyndaqel-epar-summary-public_fi.pdf)

svenska (SV) (77.11 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

02/08/2016

[View](/sv/documents/overview/vyndaqel-epar-summary-public_sv.pdf)

Vyndaqel : EPAR - Risk management plan

English (EN) (1.16 MB - PDF)

**First published:** 21/02/2020

**Last updated:** 22/11/2024

[View](/en/documents/rmp/vyndaqel-epar-risk-management-plan_en.pdf)

## Product information

Vyndaqel : EPAR - Product Information

English (EN) (486.44 KB - PDF)

**First published:** 18/11/2011

**Last updated:** 17/09/2025

[View](/en/documents/product-information/vyndaqel-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-948)

български (BG) (513.53 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/bg/documents/product-information/vyndaqel-epar-product-information_bg.pdf)

español (ES) (491.6 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/es/documents/product-information/vyndaqel-epar-product-information_es.pdf)

čeština (CS) (490.48 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/cs/documents/product-information/vyndaqel-epar-product-information_cs.pdf)

dansk (DA) (729.71 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/da/documents/product-information/vyndaqel-epar-product-information_da.pdf)

Deutsch (DE) (483.6 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/de/documents/product-information/vyndaqel-epar-product-information_de.pdf)

eesti keel (ET) (495.55 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/et/documents/product-information/vyndaqel-epar-product-information_et.pdf)

ελληνικά (EL) (508.2 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/el/documents/product-information/vyndaqel-epar-product-information_el.pdf)

français (FR) (508.72 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/fr/documents/product-information/vyndaqel-epar-product-information_fr.pdf)

hrvatski (HR) (513.73 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/hr/documents/product-information/vyndaqel-epar-product-information_hr.pdf)

íslenska (IS) (505.08 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/is/documents/product-information/vyndaqel-epar-product-information_is.pdf)

italiano (IT) (443.84 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/it/documents/product-information/vyndaqel-epar-product-information_it.pdf)

latviešu valoda (LV) (513.57 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/lv/documents/product-information/vyndaqel-epar-product-information_lv.pdf)

lietuvių kalba (LT) (517.08 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/lt/documents/product-information/vyndaqel-epar-product-information_lt.pdf)

magyar (HU) (518.11 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/hu/documents/product-information/vyndaqel-epar-product-information_hu.pdf)

Malti (MT) (555.44 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/mt/documents/product-information/vyndaqel-epar-product-information_mt.pdf)

Nederlands (NL) (503.83 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/nl/documents/product-information/vyndaqel-epar-product-information_nl.pdf)

norsk (NO) (492.1 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/no/documents/product-information/vyndaqel-epar-product-information_no.pdf)

polski (PL) (491.87 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/pl/documents/product-information/vyndaqel-epar-product-information_pl.pdf)

português (PT) (489.97 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/pt/documents/product-information/vyndaqel-epar-product-information_pt.pdf)

română (RO) (468.09 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/ro/documents/product-information/vyndaqel-epar-product-information_ro.pdf)

slovenčina (SK) (509.58 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/sk/documents/product-information/vyndaqel-epar-product-information_sk.pdf)

slovenščina (SL) (466.67 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/sl/documents/product-information/vyndaqel-epar-product-information_sl.pdf)

Suomi (FI) (504.49 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/fi/documents/product-information/vyndaqel-epar-product-information_fi.pdf)

svenska (SV) (482.46 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

17/09/2025

[View](/sv/documents/product-information/vyndaqel-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000278463 11/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vyndaqel : EPAR - All Authorised presentations

English (EN) (31.93 KB - PDF)

**First published:** 18/11/2011

**Last updated:** 10/12/2021

[View](/en/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-621)

български (BG) (33.34 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/bg/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_bg.pdf)

español (ES) (30.49 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/es/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_es.pdf)

čeština (CS) (32.13 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/cs/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (31.97 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/da/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (33.01 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/de/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (30.1 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/et/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (32.94 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/el/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_el.pdf)

français (FR) (30.37 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/fr/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (31.17 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/hr/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (31.84 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/is/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_is.pdf)

italiano (IT) (31.1 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/it/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (31.85 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/lv/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (40.41 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/lt/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (31.82 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/hu/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.27 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/mt/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (30.53 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/nl/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (32.21 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/no/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_no.pdf)

polski (PL) (32.91 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/pl/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_pl.pdf)

português (PT) (30.42 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/pt/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_pt.pdf)

română (RO) (30.95 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/ro/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.16 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/sk/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (31.08 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/sl/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (30.54 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/fi/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (31.23 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

10/12/2021

[View](/sv/documents/all-authorised-presentations/vyndaqel-epar-all-authorised-presentations_sv.pdf)

Vyndaqel : EPAR - Conditions imposed on member states for safe and effective use

English (EN) (95.21 KB - PDF)

**First published:** 18/11/2011

**Last updated:** 18/11/2011

[View](/en/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_en.pdf)

[Other languages (23)](#file-language-dropdown-496)

български (BG) (130.36 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/bg/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_bg.pdf)

español (ES) (97.69 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/es/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_es.pdf)

čeština (CS) (98.69 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/cs/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_cs.pdf)

dansk (DA) (81.29 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/da/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_da.pdf)

Deutsch (DE) (95.31 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/de/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_de.pdf)

eesti keel (ET) (93.46 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/et/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_et.pdf)

ελληνικά (EL) (108.28 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/el/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_el.pdf)

français (FR) (92.33 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/fr/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_fr.pdf)

íslenska (IS) (72.42 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/is/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_is.pdf)

italiano (IT) (97.43 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/it/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_it.pdf)

latviešu valoda (LV) (124.04 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/lv/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_lv.pdf)

lietuvių kalba (LT) (126.78 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/lt/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_lt.pdf)

magyar (HU) (108.31 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/hu/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_hu.pdf)

Malti (MT) (109.79 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/mt/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_mt.pdf)

Nederlands (NL) (87.85 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/nl/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_nl.pdf)

norsk (NO) (87.48 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/no/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_no.pdf)

polski (PL) (118.93 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/pl/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_pl.pdf)

português (PT) (102.35 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/pt/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_pt.pdf)

română (RO) (112.03 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/ro/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_ro.pdf)

slovenčina (SK) (102.9 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/sk/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_sk.pdf)

slovenščina (SL) (114.73 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/sl/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_sl.pdf)

Suomi (FI) (86.82 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/fi/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_fi.pdf)

svenska (SV) (79.53 KB - PDF)

**First published:**

18/11/2011

**Last updated:**

18/11/2011

[View](/sv/documents/conditions-member-states/vyndaqel-epar-conditions-imposed-member-states-safe-and-effective-use_sv.pdf)

Vyndaqel : EPAR - Conclusions on the granting of the marketing authorisation under exceptional circumstances - Annex IV

English (EN) (61.67 KB - PDF)

**First published:** 08/08/2013

**Last updated:** 08/08/2013

[View](/en/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_en.pdf)

[Other languages (24)](#file-language-dropdown-515)

български (BG) (105.99 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/bg/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_bg.pdf)

español (ES) (74.43 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/es/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_es.pdf)

čeština (CS) (99 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/cs/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_cs.pdf)

dansk (DA) (75.36 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/da/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_da.pdf)

Deutsch (DE) (80.63 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/de/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_de.pdf)

eesti keel (ET) (70.54 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/et/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_et.pdf)

ελληνικά (EL) (107.92 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/el/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_el.pdf)

français (FR) (82.71 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/fr/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_fr.pdf)

hrvatski (HR) (79.18 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/hr/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_hr.pdf)

íslenska (IS) (145.51 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/is/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_is.pdf)

italiano (IT) (86.15 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/it/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_it.pdf)

latviešu valoda (LV) (101.17 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/lv/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_lv.pdf)

lietuvių kalba (LT) (98.33 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/lt/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_lt.pdf)

magyar (HU) (98.54 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/hu/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_hu.pdf)

Malti (MT) (97.63 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/mt/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_mt.pdf)

Nederlands (NL) (75.22 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/nl/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_nl.pdf)

norsk (NO) (79.42 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/no/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_no.pdf)

polski (PL) (102.3 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/pl/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_pl.pdf)

português (PT) (75.62 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/pt/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_pt.pdf)

română (RO) (107.01 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/ro/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_ro.pdf)

slovenčina (SK) (88.08 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/sk/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_sk.pdf)

slovenščina (SL) (95.61 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/sl/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_sl.pdf)

Suomi (FI) (70.75 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/fi/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_fi.pdf)

svenska (SV) (74.25 KB - PDF)

**First published:**

08/08/2013

**Last updated:**

08/08/2013

[View](/sv/documents/conditions-member-states/vyndaqel-epar-conclusions-granting-marketing-authorisation-under-exceptional-circumstances-annex-iv_sv.pdf)

## Product details

Name of medicine Vyndaqel Active substance tafamidis International non-proprietary name (INN) or common name tafamidis Therapeutic area (MeSH) Amyloidosis Anatomical therapeutic chemical (ATC) code N07XX08

### Pharmacotherapeutic group

Other nervous system drugs

### Therapeutic indication

Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

## Authorisation details

EMA product number EMEA/H/C/002294

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Exceptional circumstances

This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see [Pre-authorisation guidance](/node/68554) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 21/07/2011 Marketing authorisation issued 16/11/2011 Revision 31

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vyndaqel : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (246.54 KB - PDF)

**First published:** 18/02/2025

**Last updated:** 17/09/2025

[View](/en/documents/procedural-steps-after/vyndaqel-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vyndaqel : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (294.27 KB - PDF)

**First published:** 22/04/2013

**Last updated:** 18/02/2025

[View](/en/documents/procedural-steps-after/vyndaqel-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Vyndaqel-H-C-PSUSA-00002842-202205: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/918324/2022

English (EN) (147.22 KB - PDF)

**First published:** 24/02/2023

[View](/en/documents/scientific-conclusion/vyndaqel-h-c-psusa-00002842-202205-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Vyndaqel: Orphan maintenance assessment report (post-authorisation)

Adopted

Reference Number: EMADOC-1700519818-273084

English (EN) (314.92 KB - PDF)

**First published:** 25/02/2020

[View](/en/documents/orphan-maintenance-report-post/vyndaqel-orphan-maintenance-assessment-report-post-authorisation_en.pdf)

Vyndaqel-H-C-2294-X-0049-G : EPAR - Assessment report

Adopted

Reference Number: EMA/3391/2020

English (EN) (2.07 MB - PDF)

**First published:** 21/02/2020

[View](/en/documents/variation-report/vyndaqel-h-c-2294-x-0049-g-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Vyndaqel : EPAR - Public assessment report

Adopted

Reference Number: EMA/815723/2011

English (EN) (1.34 MB - PDF)

**First published:** 18/11/2011

**Last updated:** 18/11/2011

[View](/en/documents/assessment-report/vyndaqel-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vyndaqel

Adopted

Reference Number: EMA/CHMP/546201/2011

English (EN) (117.78 KB - PDF)

**First published:** 22/07/2011

**Last updated:** 22/07/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vyndaqel_en.pdf)

#### News on Vyndaqel

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-december-2019) 13/12/2019

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Vyndaqel : EPAR - Product information - tracked changes

English (EN) (276.88 KB - DOCX)

**First published:** 17/09/2025

[View](/en/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-361)

български (BG) (338.7 KB - DOCX)

**First published:**

17/09/2025

[View](/bg/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_bg.docx)

español (ES) (294.05 KB - DOCX)

**First published:**

17/09/2025

[View](/es/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_es.docx)

čeština (CS) (355.25 KB - DOCX)

**First published:**

17/09/2025

[View](/cs/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (268.25 KB - DOCX)

**First published:**

17/09/2025

[View](/da/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (297.86 KB - DOCX)

**First published:**

17/09/2025

[View](/de/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (282.44 KB - DOCX)

**First published:**

17/09/2025

[View](/et/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (335.64 KB - DOCX)

**First published:**

17/09/2025

[View](/el/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_el.docx)

français (FR) (351.26 KB - DOCX)

**First published:**

17/09/2025

[View](/fr/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (296.75 KB - DOCX)

**First published:**

17/09/2025

[View](/hr/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (307.76 KB - DOCX)

**First published:**

17/09/2025

[View](/is/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_is.docx)

italiano (IT) (297.12 KB - DOCX)

**First published:**

17/09/2025

[View](/it/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (299.94 KB - DOCX)

**First published:**

17/09/2025

[View](/lv/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (312.06 KB - DOCX)

**First published:**

17/09/2025

[View](/lt/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (312.04 KB - DOCX)

**First published:**

17/09/2025

[View](/hu/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (288.03 KB - DOCX)

**First published:**

17/09/2025

[View](/mt/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (324.5 KB - DOCX)

**First published:**

17/09/2025

[View](/nl/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (326.46 KB - DOCX)

**First published:**

17/09/2025

[View](/no/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_no.docx)

polski (PL) (400.33 KB - DOCX)

**First published:**

17/09/2025

[View](/pl/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_pl.docx)

português (PT) (266.51 KB - DOCX)

**First published:**

17/09/2025

[View](/pt/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_pt.docx)

română (RO) (248.05 KB - DOCX)

**First published:**

17/09/2025

[View](/ro/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (292.36 KB - DOCX)

**First published:**

17/09/2025

[View](/sk/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (283.42 KB - DOCX)

**First published:**

17/09/2025

[View](/sl/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (317.27 KB - DOCX)

**First published:**

17/09/2025

[View](/fi/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (271.73 KB - DOCX)

**First published:**

17/09/2025

[View](/sv/documents/product-information-tracked-changes/vyndaqel-epar-product-information-tracked-changes_sv.docx)

#### More information on Vyndaqel

- [EU/3/12/1066 - orphan designation for treatment of senile systemic amyloidosis](/en/medicines/human/orphan-designations/eu-3-12-1066)
- [Patient outcomes and clinical characteristics of ATTR-CM patients treated with tafamidis: A single center experience in Turkey - Study ATTREAL - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000561)
- [Tafamidis Pregnancy Surveillance Study - post-authorisation study](https://catalogues.ema.europa.eu/study/47046)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 17/09/2025

## Share this page

[Back to top](#main-content)